Mark Eshoo
Director, New Technology Development, Ibis Biosciences, Inc.

With over twenty years research experience in the field of genomics and genetic analysis, Dr. Eshoo serves as the Director of New Technology Development at Ibis Biosciences, a division of Abbott Labs.  There, Dr. Eshoo leads several projects relating to development and assessment of new diagnostic technologies. He has authored numerous scientific publications on the detection of tick and mosquito-borne pathogens including alphaviruses, canine heartworm, Borrelia, Babesia, Ehrlichia, Rickettsia, Anaplasma, and flaviviruses. To develop these assays Dr. Eshoo, his collaborators, and research team have tested thousands of ticks collected from the US and Europe for a wide range of tick-borne pathogens. Results of this work have identified and characterized the breadth and depth of tick-borne pathogens in the environment. These diagnostic assays are now being applied for the detection of tick-borne pathogens from a variety of clinical specimens with the goal of better diagnosis and treatments for Lyme and other tick-borne diseases.